{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:25:55Z","timestamp":1785209155232,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,9]]},"DOI":"10.7759\/cureus.50227","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T16:11:46Z","timestamp":1702138306000},"source":"Crossref","is-referenced-by-count":6,"title":["Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Sabrina A","family":"Billings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C","family":"Prier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S","family":"Hedges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"Cervellin G","year":"2010","unstructured":"Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010, 48:749-56. 10.1515\/CCLM.2010.151","journal-title":"Clin Chem Lab Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1314-5","article-title":"Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice","volume":"20","author":"Chavez LO","year":"2016","unstructured":"Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016, 20:135. 10.1186\/s13054-016-1314-5","journal-title":"Crit Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"15","author":"Shi Q","year":"2022","unstructured":"Shi Q, Wang Y, Hao Q, et al.. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022, 15:259-69. 10.1016\/S0140-6736(21)01640-8","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1800-5","article-title":"Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey","volume":"29","author":"de Meijer AR","year":"2003","unstructured":"de Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BG, Drenth JP. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med. 2003, 29:1121-5. 10.1007\/s00134-003-1800-5","journal-title":"Intensive Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/cc13897","article-title":"Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review","volume":"18","author":"Petejova N","year":"2014","unstructured":"Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care. 2014, 18:224. 10.1186\/cc13897","journal-title":"Crit Care"},{"key":"ref7","article-title":"Myoglobinuria","author":"Anwar MY","year":"2023","unstructured":"Anwar MY, Gupta V. Myoglobinuria. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.09.020","article-title":"The syndrome of rhabdomyolysis: Pathophysiology and diagnosis","volume":"18","author":"Giannoglou GD","year":"2007","unstructured":"Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med. 2007, 18:90-100. 10.1016\/j.ejim.2006.09.020","journal-title":"Eur J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0313","article-title":"Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials","volume":"61","author":"Ostrowski P","year":"2023","unstructured":"Ostrowski P, Bonczar M, Avram AE, Lippi G, Henry BM. Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials. Clin Chem Lab Med. 2023, 61:1688-99. 10.1515\/cclm-2023-0313","journal-title":"Clin Chem Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson PD","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003, 289:1681-90. 10.1001\/jama.289.13.1681","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral BM","year":"2020","unstructured":"Cabral BM, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020, 66:101015. 10.1016\/j.disamonth.2020.101015","journal-title":"Dis Mon"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2021.06.001","article-title":"Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists","volume":"28","author":"Tommerdahl KL","year":"2021","unstructured":"Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists. Adv Chronic Kidney Dis. 2021, 28:337-46. 10.1053\/j.ackd.2021.06.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty R","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr. 2022, 16:102427. 10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Syndr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206675-rhabdomyolysis-associated-with-semaglutide-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:03Z","timestamp":1707509343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206675-rhabdomyolysis-associated-with-semaglutide-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.50227","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,9]]}}}